TAS 303

Drug Profile

TAS 303

Alternative Names: TAS-303

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Urologics
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stress incontinence

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Stress incontinence in Japan (PO) (NCT02906683)
  • 14 Sep 2016 Taiho Pharmaceutical plans an exploratory phase IIa trial for Stress incontinence in Japan (PO) (NCT02906683)
  • 01 Mar 2016 Taiho Pharmaceutical completes a phase I trial in Stress incontinence in Japan (NCT02562807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top